Novavax, Inc. (NASDAQ:NVAX) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 63,771,259 shares, a growth of 4.1% from the January 15th total of 61,262,737 shares. Based on an average daily volume of 8,256,953 shares, the days-to-cover ratio is currently 7.7 days. Currently, 16.9% of the shares of the stock are sold short.
A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded Novavax from a “buy” rating to a “hold” rating in a report on Friday, February 1st. BidaskClub raised Novavax from a “hold” rating to a “buy” rating in a report on Wednesday, January 30th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 price objective on shares of Novavax in a report on Tuesday, January 29th. HC Wainwright assumed coverage on Novavax in a report on Monday, January 28th. They set a “buy” rating and a $6.00 price objective on the stock. Finally, LADENBURG THALM/SH SH set a $4.00 price objective on Novavax and gave the company a “buy” rating in a report on Friday, January 4th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Novavax currently has an average rating of “Buy” and an average price target of $4.18.
Shares of NASDAQ:NVAX traded down $0.07 during trading on Monday, reaching $2.20. The stock had a trading volume of 6,696,840 shares, compared to its average volume of 9,107,929. Novavax has a 52 week low of $1.15 and a 52 week high of $2.75. The stock has a market capitalization of $869.07 million, a P/E ratio of -3.49 and a beta of 2.41.
ILLEGAL ACTIVITY WARNING: “Novavax, Inc. (NVAX) Short Interest Update” was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://dakotafinancialnews.com/2019/02/11/novavax-inc-nvax-short-interest-update-2.html.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Further Reading: How Do Mutual Funds Work?
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.